<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024698</url>
  </required_header>
  <id_info>
    <org_study_id>EX-MKTG-43</org_study_id>
    <nct_id>NCT02024698</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist</brief_title>
  <official_title>Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coopervision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coopervision, Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the clinical performance of PC 1-Day versus 1-Day
      Acuvue Moist each for one week of daily disposable wear.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this cross-over study is to evaluate the clinical performance of the PC-1 Day
      in comparison with 1•Day Acuvue® Moist®. In particular, the study will focus on lens wearing
      comfort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Subjective Assessment: Change in comfort and lens fit</measure>
    <time_frame>Change from baseline over 1 week for each pair V1, V2, V3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in comfort and lens fit from baseline over 1 week for each pair using questionare and rated on subjective response scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Practitioner Measurements: Change in ocular response</measure>
    <time_frame>Change from baseline over 1 week for each pair V1, V2, V3</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in ocular response from baseline over 1 week for each pair by biomicroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>omafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants are randomized to wear omafilcon A or etafilcon A pair of study lenses then crossover to the alternate pair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants are randomized to wear omafilcon A or etafilcon A pair of study lenses then crossover to the alternate pair.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>omafilcon A</intervention_name>
    <description>Study participants are randomized to wear omafilcon A or etafilcon A pair of study lenses then crossover to the alternate pair.</description>
    <arm_group_label>omafilcon A</arm_group_label>
    <arm_group_label>etafilcon A</arm_group_label>
    <other_name>Proclear 1 Day (omafilcon A)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>Study participants are randomized to wear omafilcon A or etafilcon A pair of study lenses then crossover to the alternate pair.</description>
    <arm_group_label>omafilcon A</arm_group_label>
    <arm_group_label>etafilcon A</arm_group_label>
    <other_name>1-Day Acuvue Moist (etafilcon A)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A person is eligible for inclusion in the study if he/she:

          -  Is between 18 and 40 years of age (inclusive)

          -  Have the use of a mobile phone to send and receive text messages throughout the day
             for the duration of the study.

          -  Has had a self-reported visual exam in the last two years

          -  Is an adapted soft CL wearer

          -  Must be able to wear their lenses at least 6 full days over the 7 days; 14 hours per
             day, assuming there are no contraindications for doing so

          -  Has a CL spherical prescription between - 1.00 and - 6.00 (inclusive)

          -  Has less than 0.75D spectacle cylinder in each eye.

          -  Is correctable to a visual acuity of 20/25 or better in both eyes

          -  Has clear corneas and no active ocular disease

          -  Has read, understood and signed the information consent letter.

          -  Is willing to comply with the wear schedule (at least 40 hrs per week)

          -  Is willing to comply with the visit schedule

        Exclusion Criteria:

        A person will be excluded from the study if he/she:

          -  Has never worn contact lenses before.

          -  Currently wears rigid gas permeable contact lenses.

          -  Has a history of not achieving comfortable CL wear (5 days per week; &gt; 8 hours/day)

          -  Has a CL prescription outside the range of - 1.00 to -6.00D

          -  Has a spectacle cylinder greater than -0.50D of cylinder in either eye.

          -  Has best corrected spectacle distance vision worse then 20/25 in either eye.

          -  Has any systemic disease affecting ocular health.

          -  Is using any systemic or topical medications that will affect ocular health.

          -  Has any ocular pathology or severe insufficiency of lacrimal secretion

          -  Has persistent, clinically significant corneal or conjunctival staining

          -  Has active neovascularization or any central corneal scars.

          -  Is aphakic.

          -  Is presbyopic.

          -  Has undergone corneal refractive surgery.

          -  Is participating in any other type of eye related clinical or research study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Siegel, OD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun City West Eye Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Eye Care, PLLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Zurich Eye Care</name>
      <address>
        <city>Lake Zurich</city>
        <state>Illinois</state>
        <zip>60047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs. Quinn, Foster &amp; Assoc.</name>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <zip>45701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Professionals</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>February 4, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
